STN- Structure Seasch
11/9/07

10/578,660

=> d ibib abs hitstr 1-12

L9 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:876277 CAPLUS
DOCUMENT NUMBER: 147:263366
TITLE: Liquid-filled nanodroplets containing lipids and antitumor drugs for cancer treatment
INVENTOR(S): Unger, Evan C.; Matsunaga, Terry O.; Zutshi, Reena
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007184076	A1	20070809	US 2006-349660	20060207
WO 2007092432	A2	20070816	WO 2007-US3130	20070206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-349660 A 20060207

AB A nanodroplet composition is provided, the nanodroplets include a lipid encapsulating a biol. compatible oil, a fluorocarbon composition including one or more fluorinated hydrocarbons, and a therapeutically active compound, where the fluorocarbon composition is in a liquid state at a temperature that is equal to, or lower than, the body temperature of a mammal. For example, a lipid contained paclitaxel, DPPC, PEG-DPPE, and dipalmitoylphosphatidic acid and soybean oils, and triacetin.

IT 123948-87-8, Topotecan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid-filled nanodroplets containing lipids and antitumor drugs for cancer treatment)

RN 123948-87-8 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:537782 CAPLUS
DOCUMENT NUMBER: 146:514717
TITLE: Combination treatment of cancer comprising EGFR/HER2 inhibitors
INVENTOR(S): Solca, Flavio; Amelsberg, Andree; Stehle, Gerd; Van Meel, Jacobus C. A.; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: PCT Int. Appl., 107pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007054551	A1	20070518	WO 2006-EP68314	20061109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-110669 A 20051111
OTHER SOURCE(S): MARPAT 146:514717
GI



I

AB The invention discloses a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amts. of (1) a compound I (Ra = benzyl, 1-phenylethyl, 3-chloro-4-fluorophenyl; Rb = H, C1-4 alkyl; Rc = cyclopropylmethoxy, cyclobutoxy, etc.; Rd = dimethylamino, N-cyclopropyl-N-methylamino, etc.); and (2) at least a further chemotherapeutic agent; optionally in combination with radiotherapy, radioimmunotherapy and/or tumor resection by surgery. The invention further discloses corresponding medicaments and the preparation thereof.

IT 123948-87-8, Topotecan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EGFR/HER2 inhibitor combination treatment for cancer)

RN 123948-87-8 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:435932 CAPLUS
DOCUMENT NUMBER: 146:428594
TITLE: Novel crystalline form of topotecan hydrochloride
INVENTOR(S): Pathi, Srinivas Laxminarayan; Kanathala, Shashi Rekha; Gangrade, Manish Gopaldas; Kankan, Rajendra Narayanrao; Rao, Dharmaraj Ramachandra
PATENT ASSIGNEE(S): Cipla Limited, India; Curtis, Philip Anthony
SOURCE: PCT Int. Appl., 18pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007042799	A1	20070419	WO 2006-GB3768	20061010

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

IN 2005MU01274	A	20070629	IN 2005-MU1274		20051010
US 2007105885	A1	20070510	US 2006-539932		20061010
PRIORITY APPLN. INFO.:			IN 2005-MU1274	A	20051010

AB The invention relates to a novel crystalline form of topotecan hydrochloride, and methods of making the same. Thus, 10.0 g of topotecan hydrochloride pentahydrate was suspended in 100 mL of methanol and stirred at 25-30° for 1 h and further chilled to 10-150° and stirred for 1 h at 10-15°C. The resulting solid was filtered and washed with 5 mL of methanol. The solid was dried in vacuum at 25-30° for 5 h, followed by drying at 30-35° C for 36 h to get 6.0 g of Form 'A'.

IT 119413-54-6, Topotecan hydrochloride 123948-87-8, Topotecan
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel crystalline form of hydrochloride topotecan)

RN 119413-54-6 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, hydrochloride (1:1), (4S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 123948-87-8 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:167588 CAPLUS
DOCUMENT NUMBER: 144:254148
TITLE: Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006058311	A1	20060316	US 2005-189540	20050726
AU 2005274384	A1	20060223	AU 2005-274384	20050809
CA 2576269	A1	20060223	CA 2005-2576269	20050809
EP 1827441	A1	20070905	EP 2005-770228	20050809
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
CN 101039673	A	20070919	CN 2005-80035272	20050809
IN 2007DN00888	A	20070803	IN 2007-DN888	20070202
KR 2007050478	A	20070515	KR 2007-705955	20070314

PRIORITY APPLN. INFO.:

EP 2004-19361	A	20040814
EP 2004-19448	A	20040817
WO 2005-EP8623	W	20050809

OTHER SOURCE(S): MARPAT 144:254148
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of aminopteridinones I, which are useful for the treatment of diseases which involve cell proliferation. In compds. I, R1 and R2 are independently selected from H and (un)substituted C1-6 alkyl, or R1 and R2 together form a 2- to 5-membered alkylene bridge, optionally containing 1 or 2 heteroatoms; R3 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-14 aryl, etc.; R4 is H, OH, CN, halo, (un)substituted amino, (un)substituted C1-6 alkyl, C1-5 alkoxy, etc.; L is (un)substituted C2-10 alkylene, (un)substituted C2-10 alkenylene, (un)substituted C6-14 arylene, etc.; R5 is (un)substituted morpholinyl, (un)substituted piperidinyl, (un)substituted piperazinyl, (un)substituted piperazinylcarbonyl, (un)substituted pyrrolidinyl, (un)substituted thiomorpholinyl, etc.; n is 0 or 1; and m is 1 or 2; including tautomers, stereoisomers, salts, solvates, polymorphs, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, at least one other therapeutic agent, optionally with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. for the treatment of diseases which involve cell proliferation, migration or apoptosis of cancer cells, or angiogenesis. Esterification of (R)-2-aminobutyric acid and reductive condensation with cyclopentanone gave cyclopentylamine II, which underwent regioselective substitution of 2,4-dichloro-5-nitropyrimidine and reductive heterocyclization to form pteridinone III. N-Methylation of III followed by substitution with 4-amino-3-methoxybenzoic acid and amidation with 1-methyl-4-aminopiperidine resulted in the formation of aminopteridinone IV. A combination of suboptimal doses of irinotecan and compound IV shows an additive/synergistic effect in a human colon carcinoma model and is well tolerated. Meanwhile, compound IV acts at least additively with docetaxel in a human non-small cell lung carcinoma model and not antagonistically with gemcitabine in a human adenocarcinoma model.

IT 123948-87-8, Topotecan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)

RN 123948-87-8 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:160304 CAPLUS
DOCUMENT NUMBER: 144:318801
TITLE: A study of variable hydration states in topotecan hydrochloride
AUTHOR(S): Vogt, Frederick G.; Dell'Orco, Philip C.; Diederich, Ann. M.; Su, Qiaogong; Wood, Jeffery L.; Zuber, Gary E.; Katrincic, Lee M.; Mueller, Ronald L.; Busby, David J.; DeBrosse, Charles W.
CORPORATE SOURCE: GlaxoSmithKline plc., Chemical and Pharmaceutical Development, King of Prussia, PA, 19406, USA
SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2006), 40(5), 1080-1088
CODEN: JPBADA; ISSN: 0731-7085
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Topotecan hydrochloride, a pharmaceutical compound developed as a treatment for cancer, exhibits variable hydration states in a crystalline solid form chosen for manufacturing This variability requires addnl. controls for successful development, and presents a characterization and detection challenge for anal. methods. In this study, overall water content was determined by Karl Fischer titration and thermogravimetric anal. (TGA) on topotecan HCl equilibrated at different relative humidity levels. These results, when combined with information obtained from dynamic water vapor sorption and differential scanning calorimetry (DSC), indicate that this form of topotecan HCl contains 3 mol of water integral to the crystalline structure and up to two addnl. moles of water depending on the relative humidity. Powder x-ray diffraction expts. did not detect significant differences in topotecan HCl samples equilibrated at trihydrate and pentahydrate states, and showed that the crystal lattice dimensions are not affected unless the form is dried below the trihydrate state. This behavior is typical of crystal structures with channels that can accommodate addnl. loosely bound water. To study the role of the loosely bound water in the crystal structure in more detail, solid-state 13C and 15N NMR were used to examine the differences between the hydration states. Both the trihydrate and pentahydrate states yielded similar solid-state NMR spectra, consistent with the lack of change in the crystal lattice. However, minor but readily detectable differences in the 13C spectra are observed with changes in water content. Interpretation of these data suggests that the loosely bound channel water is hydrogen-bonding to specific portions of the topotecan parent mol. Topotecan HCl trihydrate was hydrated with D2O vapor to confirm the nature and location of the channel water using 13C and 2H solid-state NMR. Despite the detectable association of the channel water with hydrogen bonding sites on the topotecan mol., 2H quadrupolar echo expts. indicate that the channel water is highly mobile at room temperature and at -60°.

IT 119413-54-6, Topotecan hydrochloride
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(variable hydration states in topotecan hydrochloride)

RN 119413-54-6 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, hydrochloride (1:1), (4S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:451134 CAPLUS
DOCUMENT NUMBER: 142:487518
TITLE: Preparation of novel crystalline form of topotecan monohydrochloride pentahydrate for treatment of viral and cancer-related diseases
INVENTOR(S): Dell'orco, Philip C.; Diederich, Ann Marie; Su, Qiaogang; Wood, Jeffrey Lee
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046608	A2	20050526	WO 2004-US37626	20041112
WO 2005046608	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004289318	A1	20050526	AU 2004-289318	20041112
CA 2545876	A1	20050526	CA 2004-2545876	20041112
EP 1689400	A2	20060816	EP 2004-810731	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1913897	A	20070214	CN 2004-80040300	20041112
BR 2004016366	A	20070313	BR 2004-16366	20041112
JP 2007510751	T	20070426	JP 2006-539849	20041112
IN 2006DN02454	A	20070413	IN 2006-DN2454	20060502

US 2007117832	A1	20070524	US 2006-578660		20060509
MX 2006PA05378	A	20060714	MX 2006-PA5378		20060512
NO 2006002616	A	20060712	NO 2006-2616		20060607
PRIORITY APPLN. INFO.:			US 2003-519160P	P	20031112
			US 2003-524574P	P	20031124
			WO 2004-US37626	W	20041112

AB Disclosed is a novel crystalline form of topotecan monohydrochloride pentahydrate, corresponding pharmaceutical compns., methods of preparation and/or use thereof to treat viral and/or cancer-related diseases. For example, topotecan monohydrochloride (6.00 kg) was dissolved in a mixture of acetone (50.4 L, 8.4 vols.) and 0.05 N HCl (26.1 L, 4.4 vols.) by heating to 58°. The resulting solution was cooled at a rate of about 1°/min, with stirring, to 40°, seeded with topotecan monohydrochloride pentahydrate seed material (5.9 g), and held at 35° for 1 h, during which time crystallization occurred. The resulting slurry was cooled to 0° at a rate of about 0.25°/min. The reaction product, topotecan monohydrochloride pentahydrate, was isolated by filtration and dried at 32° and -0.76 barG for 62 h while passing a vigorous stream of nitrogen through the vessel to yield 4.597 kg.

IT 119413-54-6, Topotecan hydrochloride
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(preparation of crystalline form of topotecan monohydrochloride pentahydrate for treatment of viral and cancer-related diseases)

RN 119413-54-6 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, hydrochloride (1:1), (4S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L9 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2004:369652 CAPLUS
DOCUMENT NUMBER:	141:388237
TITLE:	Decreased nucleotide excision repair activity and alterations of topoisomerase IIα are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II
AUTHOR(S):	Kruczynski, Anna; Barret, Jean-Marc; Van Hille, Benoit; Chansard, Nathalie; Astruc, Jackie; Menon,

Yoann; Duchier, Carole; Creancier, Laurent; Hill, Bridget T.
CORPORATE SOURCE: Division of Experimental Cancer Research, Pierre Fabre Research Center, Castres, 81106, Fr.
SOURCE: Clinical Cancer Research (2004), 10(9), 3156-3168
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The purpose of the study was to investigate the mechanisms associated with antitumor activity and resistance to F11782, a novel dual catalytic inhibitor of topoisomerases with DNA repair-inhibitory properties. For that purpose, an F11782-resistant P388 leukemia subline (P388/F11782) has been developed in vivo and characterized. Weekly subtherapeutic doses of F11782 (10 mg/kg) induced complete resistance to F11782 after 8 weekly passages. This resistant P388/F11782 subline retained some in vivo sensitivity to several DNA-topoisomerase II and/or I complex-stabilizing poisons and showed marked collateral sensitivity to cisplatin, topotecan, colchicine, and Vinca alkaloids, while proving completely cross-resistant only to merbarone and doxorubicin. Therefore, resistance to F11782 did not appear to be associated with a classic multidrug resistance profile, as further reflected by unaltered drug uptake and no overexpression of resistance-related proteins or modification of the glutathione-mediated detoxification process. In vivo resistance to F11782 was, however, associated with a marked reduction in topoisomerase IIα protein (87%) and mRNA (50%) levels, as well as a diminution of the catalytic activity of topoisomerase IIα. In contrast, only minor redns. in topoisomerases IIβ and I levels were recorded. However, of major interest, nucleotide excision repair activity was decreased 3-fold in these P388/F11782 cells and was more specifically associated with a decreased (67%) level of XPG (human xeroderma pigmentosum group G complementing protein), an endonuclease involved in this DNA repair system. These findings suggest that both topoisomerase IIα and XPG are major targets of F11782 in vivo and further demonstrate the original mechanism of action of this novel compound

IT 123948-87-8, Topotecan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(P388/F11782 cells retained sensitivity to topoisomerase I poison topotecan)

RN 123948-87-8 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:532671 CAPLUS
DOCUMENT NUMBER: 139:101145
TITLE: Preparation of thienopyrimidines as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
INVENTOR(S): Dumas, Jacques; Sibley, Robert; Wood, Jill
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055890	A1	20030710	WO 2002-US41168	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002364211	A1	20030715	AU 2002-364211	20021220
PRIORITY APPLN. INFO.:			US 2001-343048P P	20011221
			WO 2002-US41168 W	20021220

OTHER SOURCE(S): MARPAT 139:101145
GI



I

AB The title compds. [I; X = OR3, NR3R4; R1 = H, alkyl; R2 = (un)substituted cycloalkyl, Ph, (un)saturated 4-8 membered heterocyclyl containing 1-3 heteroatoms selected from O and S; R3 = H, alkyl; R4 = (CH2)mA, (CH2)pOA; A = (un)substituted cycloalkyl, (un)saturated 4-8 membered heterocyclyl containing 1-4 heteroatoms selected from N, O and S, etc.; or NR3R4 = (un)saturated 4-8 membered heterocyclyl containing 0-4 heteroatoms selected from N, O and S; m, p = 0-5; q = 0-1; q + (m or p) = 1-6], useful for the inhibiting the prolylpeptidase, inducing apoptosis and treating cancer, were prepared E.g., a 3-step synthesis of I [X = (2-thienylmethyl)amino; R1 = H; R2 = 4-(MeO2C)C6H4; q = 1], starting with thieno[3,2-d]pyrimidine-2,4-diol, was given. All exemplified compds. I were found to inhibit prolylpeptidase at or below of 10 μM.
IT 123948-87-8, Topotecan

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiproliferative agent; preparation of thienopyrimidines for inducing apoptosis and treating cancer in combination with other agents)

RN 123948-87-8 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:532653 CAPLUS

DOCUMENT NUMBER: 139:101144

TITLE: Preparation of quinazolines and quinolines as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents

INVENTOR(S): Dumas, Jacques; Sibley, Robert; Smith, Roger; Su, Ning; Chen, Yuanwei; Wood, Jill; Guernon, Leatte; Dixon, Julie; Brennan, Catherine; Boyer, Stephen

PATENT ASSIGNEE(S): Bayer Corporation, USA; et al.

SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055866	A1	20030710	WO 2002-US41176	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002361846	A1	20030715	AU 2002-361846	20021220
PRIORITY APPLN. INFO.:			US 2001-343112P	P 20011221
			WO 2002-US41176	W 20021220

OTHER SOURCE(S): MARPAT 139:101144

GI



I



II

AB The title compds. [I or II; Z = CH, N; Y = O, S; X = OR5, NR5R6; R1, R2 = H, NH2, CN, halo, OH, NO2 (wherein R1 and R2 are both not H); R3 = H, alkyl; R4 = (CH2)yR41 (R41 = (un)substituted alkyl; y = 0-2)], useful for the inhibiting the prolyl peptidase, inducing apoptosis and treating cancer, were prepared Thus, reacting 2,4,6-trichloroquinazoline (preparation given) with Me 4-(aminomethyl)benzoate.HCl in the presence of AcONa in H2O followed by treating the resulting Me 4-{[(2,6-dichloro-4-quinazolinyl)amino]methyl}benzoate with piperidine afforded I [Z = N; X = piperidino; R1 = H; R2 = Cl; R3 = H; R4 = 4-(MeO2C)C6H4CH2]. Most of the exemplified compds. I and II were found to inhibit prolylpeptidase at or below of 10 μM.

IT 123948-87-8, Topotecan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiproliferative agent; preparation of quinazolines and quinolines for inducing apoptosis treating cancer in combination with other agents)

RN 123948-87-8 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:532524 CAPLUS

DOCUMENT NUMBER: 139:101141

TITLE: Preparation of 2,4-diaminopyrimidines as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents

INVENTOR(S): Dumas, Jacques; Dixon, Julie; Sibley, Robert; Wood, Jill

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055489	A1	20030710	WO 2002-US41146	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002367172	A1	20030715	AU 2002-367172	20021220
PRIORITY APPLN. INFO.:			US 2001-343047P P	20011221
			WO 2002-US41146 W	20021220

OTHER SOURCE(S): MARPAT 139:101141
GI



I



II



III



IV

AB The title compds. [I or II; R1, R2 = H, halo, OH, etc.; R3 = H; R4 = (un)substituted alkyl, cycloalkyl, aryl, alkylaryl; or NR3R4 = (un)saturated 4-8 membered heterocyclyl which optionally contains 1-3 addnl. heteroatoms selected from N, O and S; A = III or IV; R5 = OH, OR6, NR8R9; R6 = alkyl, haloalkyl, aryl, haloaryl; R8, R9 = H, alkyl, aryl, etc.; n, m = 0-1], useful for the inhibiting prolylpeptidase, inducing apoptosis and treating cancer, were prepared E.g., a 3-step synthesis of I [A = 4-(HO2C)C6H4CH2; R1 = H; R2 = Me; R3 = H; R4 = 2-thienylmethyl], starting from Me 4-(aminomethyl)benzoate and 2,4-dichloro-5-methylpyrimidine, was given. All exemplified compds. I were found to inhibit prolylpeptidase at or below of 10 μM.

IT 123948-87-8, Topotecan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiproliferative agent; preparation of 2,4-diaminopyrimidines for inducing apoptosis treating cancer in combination with other agents)

RN 123948-87-8 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:154224 CAPLUS
DOCUMENT NUMBER: 138:193294
TITLE: Expandable gastric retention device containing pharmaceutical compositions
INVENTOR(S): Ayres, James W.
PATENT ASSIGNEE(S): The State of Oregon Acting by and Through the State Board of Higher Education On Behalf of Oregon State University, USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015745	A1	20030227	WO 2001-US46146	20011022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2456976	A1	20030227	CA 2001-2456976	20011022
AU 2002225872	A1	20030303	AU 2002-225872	20011022
EP 1416914	A1	20040512	EP 2001-995328	20011022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001017123	A	20040928	BR 2001-17123	20011022
CN 1543337	A	20041103	CN 2001-823544	20011022
JP 2005501097	T	20050113	JP 2003-520705	20011022
NO 2004000611	A	20040416	NO 2004-611	20040211
MX 2004PA01388	A	20040527	MX 2004-PA1388	20040213
US 2004219186	A1	20041104	US 2004-778917	20040213

IN 2004KN00232	A	20051230	IN 2004-KN232		20040219
ZA 2004002066	A	20050509	ZA 2004-2066		20040315
PRIORITY APPLN. INFO.:			US 2001-313078P	P	20010816
			WO 2001-US46146	W	20011022

AB The present application concerns gastric retention devices formed from compns. comprising polymeric materials, such as polysaccharides, and optional addnl. materials including excipients, therapeutics, and diagnostics, that reside in the stomach for a controlled and prolonged period of time. Dry powders of xanthan gum and locust bean gum were mixed intimately were converted to dried films. The dried films were compressed with the help of specially made punches and dies. A series of dies with decreasingly narrow internal diams. were used. A punch pushes the film from one die into the next die, followed by pushing of the film by another punch into the next die. This process takes place in succession until a point is reached where the film is small enough to put into a desired capsule size.

IT 119413-54-6, Topotecan hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(expandable gastric retention device containing pharmaceutical compns.)

RN 119413-54-6 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, hydrochloride (1:1), (4S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2002:701947 CAPLUS
DOCUMENT NUMBER:	138:297180
TITLE:	The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer
AUTHOR(S):	van Hattum, Annemarie H.; Pinedo, Herbert M.; Schluper, Hennie M. M.; Erkelens, Caroline A. M.; Tohgo, Akiko; Boven, Epie
CORPORATE SOURCE:	Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, 1081 HV, Neth.
SOURCE:	Biochemical Pharmacology (2002), 64(8), 1267-1277 CODEN: BCPCA6; ISSN: 0006-2952
PUBLISHER:	Elsevier Science Inc.
DOCUMENT TYPE:	Journal

LANGUAGE: English

AB DX-8951f or exatecan mesylate ((1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10-13(9H,15H)-dione methanesulfonate dihydrate), is a new water-soluble derivative of camptothecin. We determined the activity of DX-8951f in exptl. human colon cancer and ovarian cancer, being tumor types sensitive to camptothecins. With the use of the MTT assay, DX-8951f was more potent than SN-38 in four out of five human colon cancer cell lines and three out of four human ovarian cancer cell lines ($P<0.05$). DX-8951f was considerably more potent than topotecan in all cell lines tested ($P<0.05$). Prolonged exposure to DX-8951f resulted in a greater increase in inhibition of cell proliferation as compared to that obtained with SN-38 or topotecan ($P<0.05$). Overexpression of Pgp, MRP1, and LRP did not affect the in vitro activity of DX-8951f. DX-8951f administered daily + 5 or weekly + 2 resulted in growth inhibition <50% in two human colon cancer xenografts grown s.c. in nude mice. In three human ovarian cancer xenografts, however, >50% growth inhibition was observed at both schedules. In the OVCAR-3 human ovarian cancer model, DX-8951f showed considerably greater activity than topotecan ($P<0.01$). DX-8951f combined with cisplatin or paclitaxel did not indicate the presence of a pharmacol. interaction. In OVCAR-3 xenografts the combination was clearly more effective than DX-8951f alone, as the number of complete remissions increased substantially. In conclusion, this study shows that DX-8951f is highly potent in vitro and highly effective in exptl. human ovarian cancer in vivo. Prolonged exposure to DX-8951f in vitro greatly increased the antiproliferative effects, which may be a rationale for testing a continuous infusion schedule in the clinic. Addition of cisplatin or paclitaxel improved the in vivo antitumor effects of DX-8951f.

IT 123948-87-8, Topotecan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(activity profile of the hexacyclic camptothecin derivative DX-8951f in exptl. human colon cancer and ovarian cancer)

RN 123948-87-8 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:53:05 ON 09 NOV 2007)

FILE 'REGISTRY' ENTERED AT 09:53:18 ON 09 NOV 2007

```
                E TOPOTECAN/CN
L1            1 S E3
L2            1 S E5

     FILE 'CAPLUS' ENTERED AT 09:54:19 ON 09 NOV 2007
L3         2030 S L1
L4          167 S L2
L5         2137 S L3 OR L4
L6        50212 S MONOHYDRATE OR DIHYDRATE
L7        23051 S TRIHYDRATE OR TETRAHYDRATE OR PENTAHYDRATE
L8        69428 S L6 OR L7
L9           12 S L5 AND L8

=> d l1
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y



L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   123948-87-8  REGISTRY
ED   Entered STN:  23 Nov 1989
CN   1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
     10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
     10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (S)-
OTHER NAMES:
CN   10-Hydroxy-9-[(dimethylamino)methyl]-(20S)-camptothecin
CN   9-(N,N-Dimethylaminomethyl)-10-hydroxycamptothecin
CN   Hycamptamine
CN   Hycamptin
CN   NSC 609699
CN   SKF 104864
CN   SKF-S 104864
CN   Topotecan
CN   Topotecan lactone
FS   STEREOSEARCH
DR   133242-28-1, 138121-88-7
MF   C23 H23 N3 O5
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
       CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, DDFU, DRUGU,
       EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*,
       PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE,
       TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2019 REFERENCES IN FILE CA (1907 TO DATE)
66 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2030 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l2
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 119413-54-6 REGISTRY
ED Entered STN: 03 Mar 1989
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, hydrochloride (1:1),
(4S)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, monohydrochloride, (S)-
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, monohydrochloride,
(4S)- (9CI)
OTHER NAMES:
CN Hycamtin
CN Nogitecan hydrochloride
CN NSC 609669
CN SKF 104864A
CN SKFS 104864A
CN Topotecan hydrochloride
FS STEREOSEARCH
MF C23 H23 N3 O5 . Cl H
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOSIS, BIOTECHNO, CA,
CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS,
RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO
CRN (123948-87-8)

Absolute stereochemistry.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

167 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
167 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>